INTI (Inhibitor Therapeutics) Cyclically Adjusted Book per Share: $0.00 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Inhibitor Therapeutics Cyclically Adjusted Book per Share?

Inhibitor Therapeutics INTI Cyclically Adjusted Book per Share is $0.00 as of Mar. 2026. The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Inhibitor Therapeutics's adjusted book value per share for the three months ended in Mar. 2026 was $-0.011. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $0.00 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Inhibitor Therapeutics was -9.30% per year. The lowest was -67.30% per year. And the median was -14.40% per year.

As of today (2026-08-01), Inhibitor Therapeutics's current stock price is $0.08. Inhibitor Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $0.00. Inhibitor Therapeutics's Cyclically Adjusted PB Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inhibitor Therapeutics was 241.32. The lowest was 0.00. And the median was 0.00.


Inhibitor Therapeutics  (OTCPK:INTI) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Inhibitor Therapeutics was 241.32. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Inhibitor Therapeutics Cyclically Adjusted Book per Share Related Terms


Inhibitor Therapeutics Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Inhibitor Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibitor Therapeutics Cyclically Adjusted Book per Share Chart

Inhibitor Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.01 -0.01 0.00 0.00 0.00

Inhibitor Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

INTI vs TPST, AKTX, ICU: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, Inhibitor Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inhibitor Therapeutics Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inhibitor Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Inhibitor Therapeutics's Cyclically Adjusted PB Ratio falls into.



Inhibitor Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Inhibitor Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.011/330.2130*330.2130
=-0.011

Current CPI (Mar. 2026) = 330.2130.

Inhibitor Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.014 241.018 0.019
201609 0.011 241.428 0.015
201612 0.020 241.432 0.027
201703 0.006 243.801 0.008
201706 0.005 244.955 0.007
201709 0.003 246.819 0.004
201712 0.000 246.524 0.000
201803 0.004 249.554 0.005
201806 -0.004 251.989 -0.005
201809 -0.007 252.439 -0.009
201812 -0.011 251.233 -0.014
201903 -0.012 254.202 -0.016
201906 -0.014 256.143 -0.018
201909 -0.016 256.759 -0.021
201912 -0.018 256.974 -0.023
202003 -0.019 258.115 -0.024
202006 -0.020 257.797 -0.026
202009 -0.020 260.280 -0.025
202012 -0.020 260.474 -0.025
202103 -0.020 264.877 -0.025
202106 -0.020 271.696 -0.024
202109 -0.020 274.310 -0.024
202112 -0.020 278.802 -0.024
202203 -0.021 287.504 -0.024
202206 -0.021 296.311 -0.023
202209 -0.021 296.808 -0.023
202212 0.048 296.797 0.053
202303 0.045 301.836 0.049
202306 0.041 305.109 0.044
202309 0.038 307.789 0.041
202312 0.031 306.746 0.033
202403 0.027 312.332 0.029
202406 0.024 314.175 0.025
202409 0.020 315.301 0.021
202412 0.012 315.605 0.013
202503 0.008 319.799 0.008
202506 0.004 322.561 0.004
202509 0.000 324.800 0.000
202512 -0.007 324.054 -0.007
202603 -0.011 330.213 -0.011

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $0.00 mean?
Inhibitor Therapeutics (INTI) has a Cyclically Adjusted Book per Share of $0.00 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inhibitor Therapeutics and its competitors.
Is Inhibitor Therapeutics' Cyclically Adjusted Book per Share too high?
Inhibitor Therapeutics' current Cyclically Adjusted Book per Share is $0.00.
How does Inhibitor Therapeutics' Cyclically Adjusted Book per Share compare to TPST and AKTX?
Inhibitor Therapeutics' Cyclically Adjusted Book per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Inhibitor Therapeutics and its competitors. Inhibitor Therapeutics's current Cyclically Adjusted Book per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibitor Therapeutics stock overvalued right now?
Inhibitor Therapeutics (INTI) has a current Cyclically Adjusted Book per Share of $0.00. The current Cyclically Adjusted Book per Share is $0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Inhibitor Therapeutics (INTI), the current Cyclically Adjusted Book per Share is $0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibitor Therapeutics Business Description

Address 3014 West Palmira Avenue, Suite 302, Tampa, FL, USA, 33629-7264
Inhibitor Therapeutics Inc is a pharmaceutical development company focused on developing and potentially commercializing therapeutics based on already approved active pharmaceutical ingredients, with a primary focus on basal cell carcinoma nevus syndrome (BCCNS), also known as Gorlin Syndrome. The Company develops therapeutics with patent-protected methods of use or delivery for certain cancers and non-cancerous proliferation disorders, and focuses on therapies for basal cell carcinoma (BCC) in the United States, utilizing itraconazole, an FDA-approved drug for fungal infections, with developed intellectual property and know-how related to the treatment of cancer patients using itraconazole.